124 related articles for article (PubMed ID: 37816395)
21. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.
John T; Sakai H; Ikeda S; Cheng Y; Kasahara K; Sato Y; Nakahara Y; Takeda M; Kaneda H; Zhang H; Maemondo M; Minato K; Hisada T; Misumi Y; Satouchi M; Hotta K; Li A; Oukessou A; Lu S
Int J Clin Oncol; 2022 Apr; 27(4):695-706. PubMed ID: 35182247
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
Cascone T; Leung CH; Weissferdt A; Pataer A; Carter BW; Godoy MCB; Feldman H; William WN; Xi Y; Basu S; Sun JJ; Yadav SS; Rojas Alvarez FR; Lee Y; Mishra AK; Chen L; Pradhan M; Guo H; Sinjab A; Zhou N; Negrao MV; Le X; Gay CM; Tsao AS; Byers LA; Altan M; Glisson BS; Fossella FV; Elamin YY; Blumenschein G; Zhang J; Skoulidis F; Wu J; Mehran RJ; Rice DC; Walsh GL; Hofstetter WL; Rajaram R; Antonoff MB; Fujimoto J; Solis LM; Parra ER; Haymaker C; Wistuba II; Swisher SG; Vaporciyan AA; Lin HY; Wang J; Gibbons DL; Jack Lee J; Ajami NJ; Wargo JA; Allison JP; Sharma P; Kadara H; Heymach JV; Sepesi B
Nat Med; 2023 Mar; 29(3):593-604. PubMed ID: 36928818
[TBL] [Abstract][Full Text] [Related]
23. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
Gettinger SN; Redman MW; Bazhenova L; Hirsch FR; Mack PC; Schwartz LH; Bradley JD; Stinchcombe TE; Leighl NB; Ramalingam SS; Tavernier SS; Yu H; Unger JM; Minichiello K; Highleyman L; Papadimitrakopoulou VA; Kelly K; Gandara DR; Herbst RS
JAMA Oncol; 2021 Sep; 7(9):1368-1377. PubMed ID: 34264316
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215
[TBL] [Abstract][Full Text] [Related]
25. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Paz-Ares L; Ciuleanu TE; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Sakai H; Lingua A; Salman P; Souquet PJ; De Marchi P; Martin C; Pérol M; Scherpereel A; Lu S; John T; Carbone DP; Meadows-Shropshire S; Agrawal S; Oukessou A; Yan J; Reck M
Lancet Oncol; 2021 Feb; 22(2):198-211. PubMed ID: 33476593
[TBL] [Abstract][Full Text] [Related]
26. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.
Reck M; Ciuleanu TE; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Cheng Y; Sakai H; Paz-Ares L; Lu S; John T; Sun X; Moisei A; Taylor F; Lawrance R; Zhang X; Sylvester J; Yuan Y; Blum SI; Penrod JR; Carbone DP
Eur J Cancer; 2023 Apr; 183():174-187. PubMed ID: 36871487
[TBL] [Abstract][Full Text] [Related]
27. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.
Provencio M; Nadal E; González-Larriba JL; Martínez-Martí A; Bernabé R; Bosch-Barrera J; Casal-Rubio J; Calvo V; Insa A; Ponce S; Reguart N; de Castro J; Mosquera J; Cobo M; Aguilar A; López Vivanco G; Camps C; López-Castro R; Morán T; Barneto I; Rodríguez-Abreu D; Serna-Blasco R; Benítez R; Aguado de la Rosa C; Palmero R; Hernando-Trancho F; Martín-López J; Cruz-Bermúdez A; Massuti B; Romero A
N Engl J Med; 2023 Aug; 389(6):504-513. PubMed ID: 37379158
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
André T; Tougeron D; Piessen G; de la Fouchardière C; Louvet C; Adenis A; Jary M; Tournigand C; Aparicio T; Desrame J; Lièvre A; Garcia-Larnicol ML; Pudlarz T; Cohen R; Memmi S; Vernerey D; Henriques J; Lefevre JH; Svrcek M
J Clin Oncol; 2023 Jan; 41(2):255-265. PubMed ID: 35969830
[TBL] [Abstract][Full Text] [Related]
29. First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
Nishio M; Ohe Y; Ikeda S; Yokoyama T; Hayashi H; Fukuhara T; Sato Y; Tanaka H; Hotta K; Sugawara S; Daga H; Okamoto I; Kasahara K; Naito T; Li L; Gupta RG; Bushong J; Mizutani H
Int J Clin Oncol; 2023 Oct; 28(10):1354-1368. PubMed ID: 37548831
[TBL] [Abstract][Full Text] [Related]
30. Adverse event costs associated with first-line therapy for advanced non-small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors.
Stenehjem D; Lubinga SJ; Wu A; Betts KA
J Manag Care Spec Pharm; 2023 Sep; 29(9):1054-1064. PubMed ID: 37610116
[No Abstract] [Full Text] [Related]
31. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
[TBL] [Abstract][Full Text] [Related]
32. [Application of Neoadjuvant Immuno-chemotherapy in NSCLC].
Chen S; Zhao Z; Long H
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):284-292. PubMed ID: 33910277
[TBL] [Abstract][Full Text] [Related]
33. Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP; Ciuleanu TE; Schenker M; Cobo M; Bordenave S; Juan-Vidal O; Menezes J; Reinmuth N; Richardet E; Cheng Y; Mizutani H; Felip E; Zurawski B; Alexandru A; Paz-Ares L; Lu S; John T; Zhang X; Mahmood J; Hu N; De T; Santi I; Penrod JR; Yuan Y; Lee A; Reck M
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38346853
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.
Blank CU; Rozeman EA; Fanchi LF; Sikorska K; van de Wiel B; Kvistborg P; Krijgsman O; van den Braber M; Philips D; Broeks A; van Thienen JV; Mallo HA; Adriaansz S; Ter Meulen S; Pronk LM; Grijpink-Ongering LG; Bruining A; Gittelman RM; Warren S; van Tinteren H; Peeper DS; Haanen JBAG; van Akkooi ACJ; Schumacher TN
Nat Med; 2018 Nov; 24(11):1655-1661. PubMed ID: 30297911
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.
Schoenfeld JD; Hanna GJ; Jo VY; Rawal B; Chen YH; Catalano PS; Lako A; Ciantra Z; Weirather JL; Criscitiello S; Luoma A; Chau N; Lorch J; Kass JI; Annino D; Goguen L; Desai A; Ross B; Shah HJ; Jacene HA; Margalit DN; Tishler RB; Wucherpfennig KW; Rodig SJ; Uppaluri R; Haddad RI
JAMA Oncol; 2020 Oct; 6(10):1563-1570. PubMed ID: 32852531
[TBL] [Abstract][Full Text] [Related]
36. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
Paz-Ares LG; Ramalingam SS; Ciuleanu TE; Lee JS; Urban L; Caro RB; Park K; Sakai H; Ohe Y; Nishio M; Audigier-Valette C; Burgers JA; Pluzanski A; Sangha R; Gallardo C; Takeda M; Linardou H; Lupinacci L; Lee KH; Caserta C; Provencio M; Carcereny E; Otterson GA; Schenker M; Zurawski B; Alexandru A; Vergnenegre A; Raimbourg J; Feeney K; Kim SW; Borghaei H; O'Byrne KJ; Hellmann MD; Memaj A; Nathan FE; Bushong J; Tran P; Brahmer JR; Reck M
J Thorac Oncol; 2022 Feb; 17(2):289-308. PubMed ID: 34648948
[TBL] [Abstract][Full Text] [Related]
37. First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.
Imai H; Kijima T; Azuma K; Kishi K; Saito H; Yamaguchi T; Tanizaki J; Yoneshima Y; Fujita K; Watanabe S; Kitazono S; Fukuhara T; Hataji O; Toi Y; Mizutani H; Hamakawa Y; Maemondo M; Ohsugi T; Suzuki K; Horinouchi H; Ohe Y
Jpn J Clin Oncol; 2024 Apr; 54(4):452-462. PubMed ID: 38271158
[TBL] [Abstract][Full Text] [Related]
38. First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients.
O'Byrne KJ; Lee KH; Kim SW; Park K; Nishio M; Sakai H; Ohe Y; Fukuhara T; Kang JH; Daga H; Yu CJ; Hotta K; Tanaka H; Takeda M; Yokoyama T; Nathan FE; Lee JS
ESMO Open; 2022 Feb; 7(1):100394. PubMed ID: 35158207
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816.
Wang C; Chen KN; Chen Q; Wu L; Wang Q; Li X; Ying K; Wang W; Zhao J; Liu L; Fu J; Zhang C; Liu J; Hu Y; Ntambwe I; Cai J; Bushong J; Tran P; Lu S
ESMO Open; 2023 Dec; 8(6):102040. PubMed ID: 37922691
[TBL] [Abstract][Full Text] [Related]
40. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
Ready N; Hellmann MD; Awad MM; Otterson GA; Gutierrez M; Gainor JF; Borghaei H; Jolivet J; Horn L; Mates M; Brahmer J; Rabinowitz I; Reddy PS; Chesney J; Orcutt J; Spigel DR; Reck M; O'Byrne KJ; Paz-Ares L; Hu W; Zerba K; Li X; Lestini B; Geese WJ; Szustakowski JD; Green G; Chang H; Ramalingam SS
J Clin Oncol; 2019 Apr; 37(12):992-1000. PubMed ID: 30785829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
